Inogen

Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inogen reports revenue growth amidst challenges, eyes positive EBITDA

Inogen reported revenue growth in Q4 2022 despite challenges and aims for positive adjusted EBITDA by Q4 2023. The company successfully managed supply chain challenges and plans new product launches in 2023.
While facing challenges in DTC evolution and gross margin decline, Inogen sees promising market opportunities for sustainable growth. The company's strategic decisions to secure supply assurance and focus on innovation position it for future success.
With a focus on addressing challenges, leveraging strengths, and capitalizing on opportunities, Inogen is poised for growth and profitability in 2023. The company's commitment to managing disruptions and driving commercial strategy reflects a positive outlook for the future.

Inogen reports Q1 performance meeting expectations, eyes profitability by Q4

Inogen's Q1 2023 performance was mixed, with revenue meeting expectations but facing challenges in certain sales segments.
The company's strategic focus on patient-centric models and product expansion positions it well for future growth.
With a clear roadmap to profitability by Q4 2023 and a strong financial position, Inogen remains optimistic about its outlook.

Inogen reports Q2 revenue shortfall, focuses on strategic growth

Inogen faced challenges in Q2 2023 but is focused on strategic initiatives to drive growth and regain lost business.
The company's financial results were impacted by supply chain constraints, aggressive pricing tactics, and restructuring charges.
Opportunities for growth exist through international expansion, product enhancements, and entering new market segments.
Management's emphasis on commercial execution and innovation highlights a commitment to sustainable growth.

Inogen reports Q3 revenue decline, eyes international growth opportunities

Inogen faced revenue declines in Q3 2023, driven by challenges in direct-to-consumer and domestic B2B sales.
Despite these setbacks, the company showed strength in international B2B and rental revenue growth.
Operational efficiency improvements and strategic cost controls are crucial for addressing margin pressures and financial performance.
The acquisition of Physio-Assist underscores Inogen's commitment to expanding its product portfolio and enhancing market competitiveness.

Inogen reports $316M full-year revenue, eyes growth amid challenges

Inogen's Q4 2023 earnings call highlighted achievements, challenges, and opportunities. The company aims to drive growth through strategic priorities, innovation, and market leadership. Despite facing challenges in revenue and net loss, Inogen is focused on improving performance and capitalizing on market opportunities.

Inogen reports solid Q1 earnings, eyes growth amid market challenges

Inogen's Q1 2024 performance reflects steady revenue growth, improved gross margins, and prudent cost management. The company's strategic priorities, strong financial position, and revenue guidance for Q2 2024 signal resilience and growth potential amidst market challenges and opportunities.

Inogen reports Q2 revenue growth and profitability amidst operational challenges

Inogen's Q2 2024 performance showed revenue growth, improved gross margin, and achieved adjusted EBITDA profitability.
While facing challenges like increased operating expenses and DTC sales decline, the company is focused on sustainable profitability.
Opportunities lie in channel-specific strategies, innovation pipeline expansion, and long-term growth investments.

Inogen reports $89M Q3 revenue with improved profitability and strategic growth

Inogen delivered solid Q3 performance with revenue growth and profitability. Faces challenges in direct-to-consumer sales and net loss. Opportunities lie in improving sales force efficiency and expanding market reach. Strong financial position for future growth initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Inogen (INGN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Inogen (INGN) Is a Great 'Buy the Bottom' Stock Now

Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Inogen (INGN) Loses -24.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

GOLETA, Calif.--(BUSINESS WIRE)--Inogen to Report Third Quarter 2023 Financial Results on November 7, 2023.

Inogen to Report Third Quarter 2023 Financial Results on November 7, 2023

Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.

Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio

GOLETA, Calif.--(BUSINESS WIRE)--Inogen Completes Acquisition of Physio-Assist.

Inogen Completes Acquisition of Physio-Assist

GOLETA, Calif.--(BUSINESS WIRE)--Inogen Announces CFO Transition Plan. Names Mike Sergesketter as Interim Chief Financial Officer. Reaffirms 2023 Financial Guidance.

Inogen Announces CFO Transition Plan

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.

Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y

GOLETA, Calif.--(BUSINESS WIRE)--Inogen Recognized as a Finalist for Ragan's CSR & Diversity Awards Program.

Inogen Recognized as a Finalist for Ragan's CSR & Diversity Awards Program

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Inogen (INGN) Q2 Earnings

Inogen, Inc. (NASDAQ:INGN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Agnes Lee - Senior Vice President, Investor Relations and Strategic Planning Nabil Shabshab - President and Chief Executive Officer Kristin Caltrider - Chief Financial Officer Conference Call Participants Brett Krizman - KeyBanc Capital Markets Operator Welcome to Inogen's Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, August 7, 2023.

Inogen, Inc. (INGN) Q2 2023 Earnings Call Transcript

Inogen (INGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.02 per share a year ago.

Inogen (INGN) Reports Q2 Loss, Misses Revenue Estimates

GOLETA, Calif.--(BUSINESS WIRE)--Inogen Announces Second Quarter 2023 Financial Results.

Inogen Announces Second Quarter 2023 Financial Results

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the introduction of the Rove 6™ portable oxygen concentrator in the United States with best in class 8-year expected service life. The Inogen® Rove 6™ was launched in Europe in December 2022. Having completed the necessary regulatory processes, the expected service life of the Rove 6 will be extended from 5 years to.

Inogen Achieves Best In Class 8-Year Expected Service Life Portable Oxygen Concentrators

Aadi Bioscience

FibroGen

Silk Road Medical Inc

Theseus Pharmaceuticals

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me

Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growing bronchiectasis market.

Inogen (INGN) Inks Buyout Agreement to Expand Product Portfolio

Inogen's (INGN) revenue growth in the second quarter is likely to have been hampered by lower revenues in its business-to-business and direct-to-consumer channels.

Inogen's (INGN) Preliminary Q2 Revenues Dampened by Lower Sales

Inogen's Q1 2023 results disappointed the market, despite management's confirmation that previously issued FY23E guidance remained unchanged. New product launches, including Rove 6 distribution in Europe, should provide a modest boost to revenue in coming quarters. With a debt-free balance sheet, and ~70% of the company's market capitalization supported by cash and investments, Inogen is a potential acquisition target.

Inogen: Still Struggling, But Very Cheap - Upgrading To Buy

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company has entered into a definitive agreement to purchase Physio-Assist SAS, a privately-held company headquartered in France. Physio-Assist developed and manufactures Simeox, a technology-enabled airway clearance device with a proven efficacy and safety profile, currently used outside of the United States.

Inogen Expands Its Respiratory Product Portfolio with Acquisition of Physio-Assist

Hibbett Sports

Vimeo

Cara Therapeutics

1-800-FLOWERS.COM

NerdWallet

Semler Scientific

While the traditional approach to market success calls for patiently investing in reliable blue chips, those that want to see more immediate gains may consider small-cap stocks to buy. Here, the point is about accepting massive risk to hopefully realize massive rewards.

Hero or Zero? 7 Speculative Small-Cap Stocks to Make You Rich

GOLETA, Calif.--(BUSINESS WIRE)--Inogen to Present at 43rd Annual William Blair Growth Stock Conference.

Inogen to Present at 43rd Annual William Blair Growth Stock Conference

Inogen, Inc. (NASDAQ:INGN ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Agnes Lee – Senior Vice President-Investor Relations and Strategic Planning Nabil Shabshab – President and Chief Executive Officer Kristin Caltrider – Chief Financial Officer Conference Call Participants Mike Matson – Needham & Co. Matthew Mishan – KeyBanc Operator Welcome to Inogen's First Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode.

Inogen, Inc. (INGN) Q1 2023 Earnings Call Transcript

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall first-quarter results reflect soft performances.

Inogen (INGN) Q1 Earnings Beat Estimates, Revenues Lag

Inogen (INGN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $0.38 per share a year ago.

Inogen (INGN) Reports Q1 Loss, Lags Revenue Estimates

GOLETA, Calif.--(BUSINESS WIRE)--Inogen Announces First Quarter 2023 Financial Results.

Inogen Announces First Quarter 2023 Financial Results

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2023 financial results after the market closes on Thursday, May 4, 2023. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.

News for Inogen Stock (INGN)